We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Herpes Virus Mimics Host Defense Proteins

By Biotechdaily staff writers
Posted on 29 Aug 2002
A study has found that complement plays a key role in host defense against gamma-herpes virus (gHV) infection, and that gamma-herpes viruses have evolved an immune evasion strategy that is effective against complement-mediated antiviral responses during acute but not latent infection. More...
The study was published in the August 2002 issue of Immunology.

Healthy cells produce molecules known as regulators of complement activation (RCA) to prevent inadvertent triggering of the complement system. In the current study, researchers from Washington University School of Medicine (St. Louis, MO, USA; www.wustl.edu) used a genetically engineered strain of mouse gamma-herpes virus 68 (gHV68) which lacked a protein that mimics mouse RCA protein. They compared the effects of the normal RCA-containing virus and the mutant virus on normal mice versus mice that lacked a key complement protein, C3.

The virus strain lacking the RCA mimic protein was far less virulent than the normal virus. About 100 times more of the mutant virus was required to infect healthy mice than was the normal virus. The mutant virus grew 27 times slower than the normal strain and failed to spread to other organs during acute infection. When the genetically engineered virus was injected into mice lacking C3, it was just as virulent as the normal viruses are in normal mice, since the virus did not need to disguise itself with RCA in order to thrive.

The researchers found that while healthy mice infected with gHV68 rarely showed signs of persistent infection, this condition readily occurred in C3-deficient mice. Furthermore, during latent infections three to five times more virus could be reactivated in C3-deficient mice than in normal mice.

"These findings reveal another molecular mechanism by which viruses evade the immune system,” said study leader Dr. Herbert W. Virgin, professor of pathology and immunology and molecular microbiology at Washington University. "Our findings explicitly show that complement plays a role during persistent and latent infection, and that was unexpected. They also emphasize that we cannot study a viral protein during just one part of a virus's life cycle and assume we understand the function of that protein. It is important to look at it during all phases of infection.”



Related Links:
Washington University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.